These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
252 related items for PubMed ID: 31628117
1. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease. Wang K, Zelnick LR, Chen Y, Hoofnagle AN, Watnick T, Seliger S, Kestenbaum B. Clin J Am Soc Nephrol; 2020 Jan 07; 15(1):80-88. PubMed ID: 31628117 [Abstract] [Full Text] [Related]
2. Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study. Chen Y, Zelnick LR, Huber MP, Wang K, Bansal N, Hoofnagle AN, Paranji RK, Heckbert SR, Weiss NS, Go AS, Hsu CY, Feldman HI, Waikar SS, Mehta RC, Srivastava A, Seliger SL, Lash JP, Porter AC, Raj DS, Kestenbaum BR, CRIC Study Investigators. Am J Kidney Dis; 2021 Aug 07; 78(2):226-235.e1. PubMed ID: 33421453 [Abstract] [Full Text] [Related]
3. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations. Spithoven EM, Meijer E, Boertien WE, Sinkeler SJ, Tent H, de Jong PE, Navis G, Gansevoort RT. Am J Kidney Dis; 2013 Sep 07; 62(3):531-40. PubMed ID: 23714171 [Abstract] [Full Text] [Related]
4. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease. Messchendorp AL, van Londen M, Taylor JM, de Borst MH, Navis G, Casteleijn NF, Gaillard CAJM, Bakker SJL, Gansevoort RT, DIPAK Consortium. Clin J Am Soc Nephrol; 2018 Nov 07; 13(11):1680-1692. PubMed ID: 30254028 [Abstract] [Full Text] [Related]
5. Kidney Clearance of Secretory Solutes Is Associated with Progression of CKD: The CRIC Study. Chen Y, Zelnick LR, Wang K, Hoofnagle AN, Becker JO, Hsu CY, Feldman HI, Mehta RC, Lash JP, Waikar SS, Shafi T, Seliger SL, Shlipak MG, Rahman M, Kestenbaum BR, CRIC Study Investigators. J Am Soc Nephrol; 2020 Apr 07; 31(4):817-827. PubMed ID: 32205410 [Abstract] [Full Text] [Related]
12. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT. Am J Kidney Dis; 2010 Nov 07; 56(5):883-95. PubMed ID: 20888104 [Abstract] [Full Text] [Related]
13. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M. Clin J Am Soc Nephrol; 2017 Sep 07; 12(9):1461-1469. PubMed ID: 28705885 [Abstract] [Full Text] [Related]
14. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study. Phakdeekitcharoen B, Treesinchai W, Wibulpolprasert P, Boongird S, Klytrayong P. BMC Nephrol; 2021 May 15; 22(1):178. PubMed ID: 33992075 [Abstract] [Full Text] [Related]
15. Renal tubular dysfunction in patients with cystic disease of the kidneys. Pabico RC, McKenna BA, Freeman RB. Urology; 1998 May 15; 51(5A Suppl):156-60. PubMed ID: 9610573 [Abstract] [Full Text] [Related]
16. Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Geurts F, Xue L, Kramers BJ, Zietse R, Gansevoort RT, Fenton RA, Meijer E, Salih M, Hoorn EJ, DIPAK Consortium. Clin J Am Soc Nephrol; 2023 Nov 01; 18(11):1426-1434. PubMed ID: 37574650 [Abstract] [Full Text] [Related]
17. Baseline characteristics of the autosomal-dominant polycystic kidney disease sub-cohort of the KoreaN cohort study for outcomes in patients with chronic kidney disease. Kim H, Koh J, Park SK, Oh KH, Kim YH, Kim Y, Ahn C, Oh YK. Nephrology (Carlton); 2019 Apr 01; 24(4):422-429. PubMed ID: 29797773 [Abstract] [Full Text] [Related]
18. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ. Clin J Am Soc Nephrol; 2012 Mar 01; 7(3):479-86. PubMed ID: 22344503 [Abstract] [Full Text] [Related]
19. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF. Kidney Int; 2017 Feb 01; 91(2):493-500. PubMed ID: 27993381 [Abstract] [Full Text] [Related]
20. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT. Clin J Am Soc Nephrol; 2011 Feb 01; 6(2):361-8. PubMed ID: 20930090 [Abstract] [Full Text] [Related] Page: [Next] [New Search]